Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

Healthcare Biotechnology
ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Biogen info
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(15)
•••
Post by retiredcopon Oct 27, 2022 1:35pm
202 Views
Post# 35053703

Biogen info

Biogen infoIf this annoys anyone then good I have accomplished what I intended to do...

Biogen Lifts Profit Estimates as Investors Look to Alzheimer’s Drug

By

 

 and 

 

Biogen raised its outlook for profits and revenue on Tuesday as investors await full results of the Alzheimer’s drug, lecanemab. The Japan-based pharmaceutical firm Eisai (ticker: ESALY) and Biogen (BIIB) last month said a Phase 3 trial of lecanemab showed a slowdown in the rate of cognitive decline. While full results will be made available on Nov. 29, investors who had been prepared for the trial to fail are now waiting to see if the Food and Drug Administration will grant an accelerated approval by Jan. 6.


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities